Get the Stockscreener App
2.15
2.38%
0.05
Ac Immune Sa stock is traded at $2.15, with a volume of 82,171.
It is up +2.38% in the last 24 hours and down -6.93% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.10
Open:
$2.07
24h Volume:
82,171
Relative Volume:
0.64
Market Cap:
$215.88M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-3.0303
EPS:
-0.7095
Net Cash Flow:
$-68.17M
1W Performance:
+0.94%
1M Performance:
-6.93%
6M Performance:
-18.87%
1Y Performance:
-29.62%
1-Day Range:
$2.04
$2.15
1-Week Range:
$2.04
$2.1909
52-Week Range:
$1.4299
$3.98
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.15 | 216.29M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune SA Included in Top Momentum ScanJuly 2025 Action & Stepwise Entry/Exit Trade Alerts - mustnews.co.kr
AC Immune SA stock trendline breakdownJuly 2025 Closing Moves & Smart Swing Trading Alerts - Newser
Advanced analytics toolkit walkthrough for AC Immune SAShare Buyback & Consistent Growth Equity Picks - Newser
What’s the recovery path for long term holders of AC Immune SAWatch List & High Accuracy Investment Entry Signals - Newser
Backtesting results for AC Immune SA trading strategiesWeekly Volume Report & Capital Protection Trade Alerts - Newser
Using data models to predict AC Immune SA stock movementJuly 2025 Recap & Capital Efficiency Focused Ideas - Newser
Ranking AC Immune SA among high performing stocks via tools2025 Momentum Check & Weekly Return Optimization Alerts - Newser
Identifying reversal signals in AC Immune SAPortfolio Update Report & Weekly Breakout Opportunity Watchlist - Newser
Visual analytics tools that track AC Immune SA performanceJuly 2025 Chart Watch & Momentum Based Trading Ideas - Newser
What momentum shifts mean for AC Immune SA2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser
News impact scoring models applied to AC Immune SA2025 Analyst Calls & Entry Point Strategy Guides - Newser
Using AI based signals to follow AC Immune SAEarnings Trend Report & Trade Opportunity Analysis Reports - Newser
How to integrate AC Immune SA into portfolio analysis toolsJuly 2025 Summary & Daily Stock Momentum Reports - Newser
When is the best time to exit AC Immune SAAnalyst Downgrade & Real-Time Buy Signal Alerts - Newser
How to use Fibonacci retracement on AC Immune SAEarnings Overview Report & Safe Entry Point Identification - Newser
Chart based exit strategy for AC Immune SAMarket Rally & Weekly Market Pulse Updates - Newser
Can AC Immune SA disrupt its industryJuly 2025 Chart Watch & High Accuracy Investment Signals - 선데이타임즈
Why AC Immune SA stock attracts strong analyst attention2025 Retail Activity & Safe Entry Zone Identification - Newser
Developing predictive dashboards with AC Immune SA dataOil Prices & Growth Focused Stock Reports - Newser
Using R and stats models for AC Immune SA forecastingInvestment Timeline and ROI Summary Report - Newser
Is AC Immune SA stock poised for growthAI Swing Strategy Signal Forecasting System - Newser
Analyzing drawdowns of AC Immune SA with statistical toolsSupport and Resistance Zone Summary Chart - Newser
Is AC Immune SA reversing from oversold territoryFree Capital Preserving Trade Plan Templates - Newser
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):